What types of diseases is Tazemetostat mainly used to treat?

Tazemetostat is an oral small molecule EZH2 inhibitor, which is an epigenetic regulation targeted drug. It mainly acts on the abnormally active EZH2 enzyme (enhancer homolog 2) in tumor cells. EZH2 is a key enzyme involved in chromatin remodeling and gene silencing. It is highly expressed or mutated in a variety of malignant tumors and is an important mechanism for the growth and immune evasion of certain tumor cells. Therefore, tazerestat is mainly used to treat certain tumor types with EZH2 mutations or abnormal expression.

Currently, tazerestat has been approved by the U.S.FDA for the treatment of two types of malignant tumors: the first is relapsed or refractory follicular lymphoma (FLFL span>), especially patients carrying EZH2 gene mutations; the second type is metastatic or locally advanced epithelioid sarcoma (epithelioid sarcoma), this disease is relatively rare and traditional treatments are limited. The targeted mechanism of action of tazerestat provides a new treatment option for such patients.

In follicular lymphoma, tazerestat is used in patients who have relapsed after at least two prior systemic therapies. Clinical studies show that even patients with the EZH2 wild type may benefit from the drug, but the response rate is slightly lower than that of patients with the EZH2 mutation. It provides patients with refractory lymphoma with an oral, less toxic and clear-efficacy targeted treatment option, improving disease control rate and quality of life.

In general, tazerestat has demonstrated clear targeting advantages in the treatment of EZH2 related tumors, especially in follicular lymphoma and epithelioid sarcoma. As more clinical trials advance, its indications are expected to be further expanded to other tumors related to epigenetic abnormalities, such as various types of non-Hodgkin lymphoma, malignant glioma, etc., bringing new options for precise treatment to more patients.

Reference materials:https://www.tazverik.com/